Background: CD4 T lymphocyte (CD4) is the most important marker that has been used in the management of HIV. The CD4 cell count provides information on the overall immune function of an HIV-infected patient. There is an overwhelming evidence that early initiation of HAART, at higher CD4 cell count will lead to virological and immunological success, prevent disease progression and reduces the social and economic costs of advanced HIV-related illness. We investigated the trend of CD4 cell count at initiation of HAART among HIV patients in KKS. Materials and Method: All registered HIV patients from year 2012 to 2017 were enrolled in this study. Data was collected retrospectively from patient's data base and clinic's registry using a standardized data collection form. The data was analyzed by using SPSS version 16.0 and presented with percentages, mean and median values. We also compared the CD4 cell count at HAART initiation with recommendation in Malaysian Consensus Guideline on Antiretroviral. Additionally, we investigated the possible factors that lead to late initiation of HAART. Results: Mean and median values of CD4 cell count at initiation of HAART were 411.03 cell/mm 3 and
Introduction
CD4 T lymphocyte (CD4) is the most important marker that has been used in the management of HIV (Kumar et al.,2017) . The CD4 cell count provides information on the overall immune function of an HIV-infected patient (Kumar et al., 2017) . The measurement is critical in establishing thresholds for the initiation and discontinuation of antibiotics for opportunistic infection prophylaxis and in assessing the urgency to initiate highly active antiretroviral therapy (HAART) (Kumar et al.,2017) .
There is an overwhelming evidence that early initiation of HAART, at higher CD4 cell count will lead to virological and immunological success, prevent disease progression and reduces the social and economic costs of advanced HIVrelated illness (Asfaw et al.,2015) . Effective treatment averts death and also prevents transmission of HIV among serodiscordant couples (Asfaw et al.,2015) . On the other hand, starting HAART at low CD4 cell counts results in acquired immunodeficiency syndrome (AIDS) defining disease for many patients (Yamashita et al.,2001) . Studies also revealed that HIV patients who started HAART with a CD4 cell count <200 cells/mm 3 may not reach a normal CD4 cell count (Yamashita et al.,2001 ).
Initiation of HAART at higher CD4 cell counts has proven to have greater clinical benefits. (Consensus Guideline,2014) . In 2017, the guideline have been updated where it recommends initiating therapy to all HIV patients regardless of CD4 count with priority for patients with advanced HIV clinical disease, individuals with CD4 count ≤350 cells/mm3, HIV-associated nephropathy (HIVAN), HIV/Hepatitis B virus co-infection, HIV/Hepatitis C virus co infection and pregnant ladies (Consensus Guideline, 2016) .
Eventhough there are many guideline that can be use as a reference, the initiation of HAART can be very challeging and subjective. Several studies have been done worlwide to see the trend of CD4 cell count at initiation of HAART. The Korea HIVAIDS cohort study reported that the median values of CD4 cell count at HAART initiation was 181 cells/mm3 (Kiertiburanakul et al.,2014) . Studies in 13 Asia country revealed that the overall median CD4 cell count at HAART initiation was 150cells/mm3 (Kiertiburanakul et al.,2014) . Studies conducted in sub-Saharan Africa, South America and Asia reported the median CD4 count at start of therapy was 115 cells/mm3 [11] . All these studies concluded that CD4 cell count at HAART initiation was found to be very low (Kim et al., 2017) (Kiertiburanakul et al.,2014 ) (ART-LINC). In Malaysia respectively, there is lack of published study regarding the trend of CD4 cell count. Therefore, this study was designed to analyze the trend of CD4 cell count at initiation of HAART among HIV patients in Klinik Kesihatan Seremban and identify any possible factors that can lead to late initiation of HAART (HAART initiated at CD4 cell count ≤200cells/mm 3 ).
Materials and Method
This study was a retrospective study conducted in the pharmacy unit of Klinik Kesihatan Seremban (KKS). All registered HIV patients from year 2012 to 2017 were included in this study. Data was collected from patient's data base and clinic's registry using a standardized data collection form. Approval from the Malaysian Research Ethics Committee (MREC) and Clinical Research Centre through National Medical Research Register (NMRR) was obtained prior to the study. All information from the data collection was kept private and confidential. In this study, data on demographic status and CD4 cell count at diagnosis and HAART initiation were included. The data was analyzed by using SPSS version 16.0 and presented with percentages, mean and median values. Additionally, we investigated the possible factors that lead to late initiation of HAART (Initiation of HAART at CD4 less than 200 cell/ml). In this study, we also compared the CD4 cell count at HAART initiation with recommendation in Malaysian Consensus Guideline on Antiretroviral. This was to identify if HAART initiation in Klinik Kesihatan Seremban (KKS) comply to the National Guideline.
Results

1) Demographic data of HIV patients in KKS
As of December 2017, 64 patients were diagnosed with retroviral disease in KKS. All of these patients were included in this study. Based on Table 1 , 87.5% (n=56) were male patients and 12.5% (n=8) were female patients. Most patients belong to age group of 31-40 (n=25, 39.1%) followed by age group of 20-30 (n=22, 34.4%), age group 41-50 (n=8, 12.5%) and age group 51-60 (n=7, 10.9%). The least patients belong to age group of 61-70 (n=2, 3.1%). As for ethnicity/race of patients, 60.9% (n=39) were Malay, 20.3% (n=13) were Indian, 14.0% (n=9) were Chinese and the remaining (4.7%, n=3) belong to other ethnicity. Malay patients make the greatest number. Patients were exposed to HIV via sexual and intravenous drug use (IVDU). Most of them were heterosexual (50%, n=32), followed by homosexual (37.5%, n=24), bisexual (1.6%, n=1). IVDU patients contribute about 10.9% (n=7) of total population. Additionally, it showed that 9.3% (n=6) of patients were co-infected with hepatitis B and hepatitis C whereas 3.1 %( n=2) were coinfected with tuberculosis. 
4) Comparison with Malaysian Consensus Guideline on antiretroviral therapy (ART)
Based on Table 5 , generally the initiation of HAART in KKS comply to Malaysian consensus Guideline except in 2013 and 2015. In 2013 and 2015, HAART has been initiated at higher CD4 counts compared to what is recommended. This serve no harm to the patient as starting HAART at higher CD4 cell will reduce the morbidity and mortality associated with HIV infection and prevent transmission.
Discussion
In this study, we observed that the overall median CD4 cell count at the time of diagnosis was 379 cell/mm3. This finding is higher when compared with other studies conducted in Asia, Korea, South America and Sub-Saharan Africa, which ranged from 67 cell/mm3 to 247 cell/mm3 (Kim et al.,2017) (Kiertiburanakul et al.,2014) . The median CD4 cell count at diagnosis was lower than 350 cell/mm3 in 2012-2013 period and has increased to more than 350 cell/mm3 in 2014-2017 period. This finding is similar to previous study in other countries. In Korea HIV/AIDS cohort study, 76% of newly infected HIV patients from 2010-2012 were diagnosed at CD4+ cell count lower than 350 cells/mm3 with overall median CD4+ cell count 195 cells/mm3. However, in the three most recent years (2013) (2014) (2015) , the number of patients with CD4+ cell counts of more than 350 cells/mm3 at the time of diagnosis has increased (Kim et al.,2017) . In the United Kingdom, 49% of newly infected HIV patients in 2011 were diagnosed at CD4+ cell count lower than 350 cells/mm 3 which was defined as late HIV diagnosis (V Delpech et al.,2013) . Study in New York city showed that the median CD4 cell count at diagnosis increased from 325 cell/mm3 in 2006 to 379 cell/mm3 in 2015 (Sarah et al.,2016) .
Our study also showed that number of HIV patients receiving treatment from HIV Unit KKS has increased dramatically in 2016 and 2017. The finding of increasing median CD4 cell count at diagnosis and increasing number of HIV patient in primary healthcare facilities may be explained in part by several synergistic factors associated with improved primary healthcare access in Malaysia. To scale up access to HIV screening and treatment, HIV services has been decentralized to primary health facilities, closely linked with the main hospitals, along with the desire to make health care accessible, acceptable and affordable to the whole community. As of December 2015, about 90% (225) of Family Medicine Specialist country wide have been trained in HIV care and 50 mobile CD4 point of care test have been placed in primary care clinics. In 2015, HIV screening programme was available in 1 Malaysia Clinic (Global AIDS,2016).
The overall median CD4 cell count at initiation of HAART was 314 cell/mm 3. Again, this finding was found to be higher when compared with Asia study with overall median CD4 of 150 cell/mm 3 . Similar to previous study in Asia, median CD4+ Cell count at HAART initiation in our study was low in 2012 and increased over time especially beyond 2014, which was the time Malaysian Consensus Guideline on ART have been revised the recommendation on CD4 cell count threshold for ART initiation. In 2014, the guideline suggested initiate ART in asymptomatic HIV-positive patient if CD4 cell count less than 350 cell/mm 3 (Consensus Guideline,2016) . In TAHOD-TASER Cohort Study, median CD4 cell count at the start of treatment was 115 cell/mm 3 in 2008 and has increased substantially to 302 cell/mm3 after 2011 (Kiertiburanakul et al.,2014) . This CD4+ (Shen et al.,2011) .
At the same time, we found that the overall number of patients who started HAART in KKS increased sharply on 2016 and 2017. In 2012, only 2 patients had been receiving HAART in KKS. However, this value increases in 2016 and 2017 with 9 patients and 22 patients respectively. Generally, based on the finding presented in Table 5 Recently published results of the START randomized controlled trial provide the first evidence of the clinical benefits of early ART initiation after HIV diagnosis, including major reductions in serious AIDS-related events, serious non-AIDS-related events, and death [17] . Of 41 (64% of total) patients who were initiated on HAART from 2012-2017 in KKS, 13(31.7%) were late initiator, primarily due to late presenter. It showed that these patients were presented in KKS with low CD4 count (CD4 less than 200 cell/mm 3 ). This finding is consistent with Korea study where it was reported that the increased in late initiation of HAART in recent years is primarily due to an increasing proportion of late presenters. In this study, the number of late initiator was lower with 31.7% in comparison with MASTER Cohort with 54% (Elena et al.,2016) . Several factors were found to be associated with late presentation such as male gender, older age, migration, injecting drug users (IDU),and heterosexual HIV exposure (Elena et al.,2016 ) (Su Jin et al.,2016 . In spite of the availability and accessibility of HIV testing opportunities and efforts, some people are being late to test in the course of HIV infection. Late presentation into care and consequent delays in ART initiation are associated with more HIVrelated, opportunistic infections, increased morbidity and mortality, diminished responses to ART, and health care expenditures (Su Jin et al.,2016) . In order to achieve earlier entry into care, efforts to reduce the patients who first seek HIV care at the late stage are needed.
Our study has limitations. The low number of patients recruited for this study caused an obvious limitation in the interpretation of findings of this study and its power. Additional survey in multiple zones ofthe state or country with larger populations will help to endorse these results. This study also does not compare the CD4 cell count at diagnosis with baseline characteristic data susch as gender,race, transmission route and coinfection. However, we strongly believed that the data of this study provides a basic understanding of immune status of HIV patients in KKS at diagnosis and initiation of HAART.
Conclusion
In conclusion, the median CD4 cell count at diagnosis and HAART initiation in KKS was found to be high. However, the reducing trend of CD4 cell count at HAART initiation from 2016 to 2017 is of concern. Although more than half of total HIV patients in KKS were on treatment, there was a significant number of patients were still late to receive HAART. Earlier HAART initiation at higher CD4 cell count remains a challenge. We recommend a strategic interventions to increase earlier detection of HIV patients and earlier start of HAART at higher CD4 cell count to prevent HIV transmission and improve mortality and morbidity.
